In this e-book, Lonza experts review important aspects of developing and manufacturing bispecific antibodies (bsAbs), with editorial highlights from the past year. Read on to discover the impact that poor assembly and expression can have on downstream purification and formulation, and how addressing these challenges at an early stage, using specialized strategies and technologies, ensures cost-effective production of high quality bsAb-based drug candidates to tight timelines.

By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.

Latest content
Latest briefing from the Knowledge Center